Continuous Glucose Monitor (CGM) Cost & Insurance Coverage (2026)

Continuous glucose monitors have transformed diabetes management—but their cost and insurance coverage remain confusing for millions of patients. The good news: a landmark 2024 CMS rule change significantly expanded Medicare CGM coverage to many Type 2 patients not on insulin. BillKarma data shows 44% of initial CGM denials are overturned on appeal—making CGM one of the most worthwhile coverage battles to fight. Here is everything you need to know about CGM costs and coverage in 2026.

1. CGM devices and what they cost without insurance

Three major CGM systems dominate the market in 2026. Costs below reflect retail prices without insurance or patient assistance programs:

Annual CGM costs without insurance can reach $3,600–$4,800 for Dexcom G7 or $1,200–$1,800 for Libre 3. These ongoing supply costs are a major burden for uninsured and underinsured patients—which is why understanding coverage options and patient assistance programs is essential.

2. Commercial insurance coverage

Coverage for CGMs under commercial insurance has expanded significantly from 2020 to 2026, but it remains inconsistent across plans:

• Type 1 diabetes: Covered by virtually all commercial plans. CGMs are considered standard of care for Type 1 diabetes management. Prior authorization is usually required but approvals are routine for established Type 1 patients on insulin.
• Type 2 diabetes on insulin: Covered by most commercial plans. Documentation of insulin use (basal or multiple daily injections) is typically required. Prior auth required at most plans.
• Type 2 diabetes on non-insulin medications: Coverage varies significantly by plan. Some plans require step therapy (trial of fingerstick glucose monitoring before approving CGM). Denial rates are higher in this category, but appeal success is also high—especially since the 2024 CMS guidance has influenced commercial payer policies.
• Prediabetes: Rarely covered. Considered preventive rather than therapeutic for insurance purposes in most plans.

CGMs are covered as a pharmacy benefit on some plans (like a prescription) and as a DME benefit on others. The benefit category matters because your pharmacy deductible and DME deductible may differ. Ask your insurer which benefit category applies to your CGM before ordering.

3. Medicare coverage and the 2024 CMS rule change

Medicare Part B covers CGMs as durable medical equipment (DME). Coverage has historically been limited, but a major 2024 rule change dramatically expanded eligibility:

Coverage before 2024: Medicare covered CGMs only for patients with diabetes who were on intensive insulin therapy (multiple daily injections or insulin pump use). Type 2 patients on basal insulin only, oral medications, or no medications were generally not eligible.

The 2024 CMS rule change: Effective January 2024, Medicare expanded CGM coverage to include patients with diabetes who are on any insulin therapy (including basal insulin) or on a sulfonylurea—a class of oral diabetes medications that can cause hypoglycemia. This is a major shift because:

• Millions of Type 2 patients on once-daily basal insulin (glargine, detemir, degludec) who were previously ineligible are now covered.
• Type 2 patients on sulfonylureas (glipizide, glyburide, glimepiride) who are not on insulin at all are now eligible.
• The rationale is that both insulin and sulfonylureas carry hypoglycemia risk—making real-time glucose monitoring clinically valuable and medically necessary.

Medicare cost-sharing: Medicare Part B covers 80% of the approved CGM amount after the annual Part B deductible ($257 in 2026). You pay 20%. If you have a Medigap supplement, it typically covers the 20% coinsurance. Medicare Advantage plans may have different cost-sharing rules.

4. Therapeutic vs. non-therapeutic CGMs

Medicare distinguishes between two types of CGMs based on clinical use:

Therapeutic CGM: The patient uses CGM readings to make treatment decisions—like adjusting insulin doses or deciding to eat something to prevent a low—without confirming the reading with a fingerstick blood glucose test. Medicare covers therapeutic CGMs at a higher reimbursement rate (HCPCS K0553). Most modern CGMs (Dexcom G7, Abbott Libre 3) are designed and FDA-cleared as therapeutic systems.

Non-therapeutic CGM: The patient uses the CGM for trend information only, and must confirm all readings with a fingerstick before making treatment decisions. These devices bill under K0554 at a lower rate. Non-therapeutic CGMs are less common in current clinical practice.

The therapeutic designation matters because it directly affects reimbursement. A supplier who bills a therapeutic CGM under the non-therapeutic code (K0554 instead of K0553) will be underpaid by Medicare—and may pass that underpayment to the patient as a balance bill. Conversely, billing a non-therapeutic device under the therapeutic code is overbilling. Make sure the HCPCS code on your bill matches the actual device prescribed.

5. Prior authorization and step therapy

Prior authorization is required for CGMs under most commercial insurance plans and Medicare Advantage. Here is the typical process:

1. Physician prescribes the CGM with a specific brand and model documented in the order.
2. The DME supplier (or pharmacy) submits the PA request to your insurer with supporting clinical documentation from your prescribing physician.
3. Required documentation typically includes:
   • Diabetes diagnosis (Type 1 or Type 2) with ICD-10 code
   • Current medication regimen (insulin type/dose, or sulfonylurea name/dose)
   • History of hypoglycemic episodes or A1C documentation
   • Physician attestation that CGM is needed for treatment management
4. Step therapy may be required at some plans: you may need to demonstrate that you used fingerstick glucose monitoring for a defined period (typically 3–6 months) before the insurer will approve CGM. Document all fingerstick test strip prescriptions and refill history.
5. If denied, your physician can request a peer-to-peer review. Success rates are high, particularly for patients with documented hypoglycemia history or poor A1C control on current regimen.

6. HCPCS codes and common billing errors

Supplier upcoding: A common abuse pattern is DME suppliers billing for CGM components at maximum allowed quantities even when the patient received fewer supplies. For example, billing 30 days of A9276 sensors when only a 14-day supply was dispensed. Review your EOB and compare the quantity billed to what you actually received.

Quantity limits: Medicare and most insurers set quantity limits for CGM sensors. For a 14-day sensor (like the Libre 3), Medicare allows up to approximately 26 sensors per year (one every two weeks). Billing above these quantity limits is a common denial trigger and audit target.

7. Lower-cost options and patient assistance programs

If you are uninsured, underinsured, or facing a coverage denial while awaiting appeal, these options can reduce your CGM costs:

• Dexcom ACCESS Program: Provides free or reduced-cost Dexcom CGM supplies to uninsured and underinsured patients who meet income eligibility requirements. Apply at dexcom.com/access.
• Abbott myFreestyle Program: Abbott offers patient assistance for FreeStyle Libre sensors. Eligible patients may receive sensors at low or no cost. Apply through your prescribing physician or at freestylelibre.us.
• GoodRx: Can reduce out-of-pocket costs for CGM sensors dispensed at retail pharmacies. Works best for FreeStyle Libre products available at standard pharmacies.
• FreeStyle Libre 2 OTC (temporary bridge): If you are waiting for prior auth approval, the OTC Libre 2 (~$75/month without prescription) can serve as a temporary bridge. You will not be reimbursed for OTC purchases, but it provides coverage during the authorization gap.
• State programs: Some state Medicaid programs have expanded CGM coverage beyond federal Medicare requirements. Check your state’s Medicaid coverage policies if you are Medicaid-eligible.

Frequently asked questions

Sources

• Centers for Medicare & Medicaid Services: CGM Coverage Determination (January 2024)
• CMS: HCPCS Code Lookup — CGM Supplies A9276–A9278, K0553–K0554
• American Diabetes Association: Standards of Care in Diabetes (2026)
• Dexcom: ACCESS Program for Uninsured Patients
• Abbott: myFreestyle Patient Assistance Program
• JAMA: CGM Use in Type 2 Diabetes — Clinical Evidence Review (2024)
• KFF: Diabetes Device Coverage Under Medicare Part B (2025)